Moleculin Biotech has enrolled 45 subjects in its pivotal Phase 2B/3 MIRACLE trial assessing Annamycin combined with cytarabine for relapsed/refractory acute myeloid leukemia, with interim data unblinding anticipated mid-2026. The company’s immuno-oncology candidate WP1066 advances pediatric brain tumor programs, supporting pipeline diversification. Despite no revenues and ongoing operating losses driven by clinical development, the firm maintains a cash balance of $8.9 million at year-end 2025 and a current ratio of 1.41, reflecting constrained but sufficient near-term liquidity. Capital structure is equity-centric with recent fundraising bolstering the balance sheet, while no dividends or share repurchases have been declared. Upcoming data releases and regulatory feedback are key catalysts amid typical clinical-stage risks.